Inicio・Lista de Acciones・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Abierto

33.07 -0.09

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

32.1

Máximo

33.58

Métricas clave
By Trading Economics
Ingresos	43M 13M
Ventas	29M 107M
BPA	0.25
Margen de beneficios	12.139
Empleados	524
EBITDA	25M 17M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+111.53% upside

Dividendos
By Acuity
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	200M 1.6B
Apertura anterior	33.16
Cierre anterior	33.07

Immunocore Holdings PLC ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2026, 19:51 UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

3 ago 2026, 20:03 UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

31 jul 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

28 jul 2026, 19:56 UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

27 jul 2026, 18:06 UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

24 jul 2026, 15:26 UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

22 jul 2026, 19:16 UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

21 jul 2026, 21:01 UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

20 jul 2026, 20:06 UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Comparación entre iguales

Cambio de precio

Immunocore Holdings PLC ADR previsión

Precio Objetivo

By TipRanks

111.53% repunte

Estimación a 12 Meses

Media 68.6 USD 111.53%

Máximo 100 USD

Mínimo 35 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Immunocore Holdings PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Immunocore Holdings PLC ADR Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.